PTK7-Targeting Antibody CDR Engineering for Specific Signaling Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic methods for diseases associated with overexpression of PTK7, such as cancer, lack effective antibodies that can specifically target and inhibit PTK7 signaling.
Innovation Solution
Development of an antibody or its fragment with specific CDR sequences (SEQ ID NOs: 1 to 6) that bind to human PTK7, including chimeric, humanized, or human antibodies, capable of inhibiting PTK7 signaling.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing antibodies are used to target PTK7, then therapeutic effect is achieved, but specificity and effectiveness are insufficient
Solution Approach 1:
The patent applies parameter changes by optimizing the complementarity determining regions (CDRs) of the antibody through specific amino acid sequence modifications. The heavy chain CDRs (SEQ ID NOs: 1-3) and light chain CDRs (SEQ ID NOs: 4-6) are designed with precise amino acid sequences that enhance binding specificity to PTK7, thereby improving both the specificity and therapeutic reliability simultaneously
2Reliability
If conventional antibodies are used, then PTK7 binding is achieved, but immunogenicity and side effects increase
Solution Approach 1:
The patent applies local quality by humanizing specific regions of the antibody structure. The framework regions are designed to have at least 80% sequence identity to human antibody sequences, while the CDRs maintain the necessary binding specificity. This localized humanization approach reduces immunogenicity and side effects while preserving PTK7 binding capability
Solution Approach 2:
The patent modifies the amino acid sequences of the antibody at critical positions to achieve humanization. The heavy chain variable region (SEQ ID NO: 7) and light chain variable region (SEQ ID NO: 8) are designed with specific amino acid sequences that match human antibody characteristics, thereby reducing immunogenicity while maintaining binding function
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibody effectively targets and inhibits PTK7, providing a potential therapeutic approach for cancers with up-regulated PTK7 expression, including colon cancer and leukemia, with reduced immunogenicity and side effects.
Implementation Method 1
complementarity determining regions (CDR-H1 to CDR-H3) of a heavy chain variable region (VH region) include each of amino acid sequences set forth in SEQ ID NOs: 1 to 3, and complementarity determining regions (CDR-L1 to CDR-L3) of a light chain variable region (VL region) include each of amino acid sequences set forth in SEQ ID NOs: 4 to 6
Data Source
Figure 1~2
Figure 3~4
Figure 5
AI summary
An antibody or a fragment thereof, in which complementarity determining regions (CDR-H1 to CDR-H3) of a heavy chain variable region (VH region) include each of amino acid sequences set forth in SEQ ID NOs: 1 to 3, and complementarity determining regions (CDR-L1 to CDR-L3) of a light chain variable region (VL region) include each of amino acid sequences set forth in SEQ ID NOs: 4 to 6.